Skip Ribbon Commands
Skip to main content
Menu

Laboratory of Liver Cancer Functional Genomics

​Research head:​A/Prof Caroline G. LEE
​Research team:

​Yu JIN

Shi Hui GOH

Lee Jin LIM

Jade LEE

Wai Yeow LEE

Yu Pei NEO

Seung Hoon WOO

Yong Zher KOH

Maulana BACHTIAR

Steven Setiawan THENG

Wei Sheng LOO

Peter HE

Weitai HUANG

Samuel WONG

Jun Yan LOH

Shuaichen LIU

Jian HAN


There are three major focus in the Liver Cancer Functional Genomics Laboratory. The first is to understand the role of chronic inflammation in tumorigenesis for the development of intervention strategies. Our laboratory has identified FAT10 as a molecule that plays an important role in liver cancers associated with chronic inflammation, and we seek to understand how polymorphisms in the molecule will modulate the risk for cancer. We also aim to develop strategies to target this molecule. The second major focus is to elucidate the role of hepatitis B virus (HBV) in cancer development. We have comprehensively characterised the integration of HBV into the host genome in HCC patients at both the genomic and transcriptomic levels, and observed chimeric HBV-human transcripts with variable potential to induce tumorigenesis. The third major focus of the laboratory is to elucidate the role of various non-coding RNAs (including circular RNA, microRNAs and long noncoding RNAs) in hepatocellular carcinoma. Our laboratory has employed an integrative big data approach to identify clinically relevant networks of non-coding RNAs in the cancer pathway. We will characterise these networks of non-coding RNAs for their tumorigenic potential to identify novel molecular biomarkers that can be used
to help detect liver cancer at an early stage more accurately, predict patient responses to specific treatments, and identify targets for therapy.


Selected publications:

1. Hung Huynh, Lee Liek Yeow, Goh KY, Richard Ong, Huai-Xiang Hao, Alan Huang, et al. Infigratinib mediates growth inhibition and vascular normalization, impairs metastasis and improves chemotherapy in hepatocellular carcinoma. Hepatology. 2019 March; 69(3):943-958


2. Huynh H, Ong R, Goh KY, Lee LY, Puehler F, et al. Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β catenin pathway in xenograft models of hepatocellular carcinoma. Int J Oncol. 2019 Mar;54(3):1123-1133


3. Kumar R, Coronel L, Somalanka B, Raju A, Aning OA, An O, Ho YS, Chen S, Mak SY, Hor PY, Yang H, Lakshmanan M, Itoh H, Tan SY, Lim YK, Wong APC, Chew SH, Huynh TH, Goh BC, Lim CY, Tergaonkar V, Cheok CF. Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nature Communication. 2018 Sept 26; 9(1):3931


4. Huynh H, Ong R, Zopf D. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. J Exp Clin Cancer Res. 2015;34:132


5. Huynh H, Hao HX, Chan SL, et al. Loss of tuberous sclerosis complex 2 (TSC2)
is frequent in hepatocellular carcinoma and predicts response to mTORC1
inhibitor Everolimus. Mol Cancer Ther. 2015;14:1224–1235.